Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Last trade$1.29
Day change+$0.035 (+2.80%)
Day range$1.25 – $1.32
Volume1,535,789
Market cap$121M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$120.6M
Price / earnings
—
Price / book
6.45×
Price / sales
0.75×
EV / sales
1×
EV / EBITDA
-13.34×
Profitability
Earnings per share
-$0.24
Return on assets
-17.49%
Return on equity
-123.36%
Dividend yield
0%
Liquidity and leverage
Debt / equity
3.3×
Current ratio
2.01×
Quick ratio
1.82×
Cash ratio
0.82×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$9.58M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for STIM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$41.96M
$41.57M
$34.45M
$41.78M
$37.3M
$38.11M
$31.98M
$22.49M
Cost of revenue
$20.07M
$20.35M
$18.3M
$20.07M
$20.19M
$20.35M
$16.24M
$7.6M
Gross profit
$21.89M
$21.22M
$16.15M
$21.7M
$17.11M
$17.76M
$15.74M
$14.89M
Selling, general and administrative
$20.16M
$21.39M
$23.79M
$25.08M
$22.93M
$24.02M
$25.14M
$20.59M
Research and development
$1.19M
$1.34M
$1.36M
$1.67M
$1.5M
$1.8M
$1.62M
$5.77M
Total operating expenses
$21.35M
$22.72M
$25.15M
$26.75M
$24.43M
$25.82M
$26.75M
$26.37M
Operating income
$541K
-$1.5M
-$9M
-$5.04M
-$7.32M
-$8.06M
-$11.01M
-$11.47M
Interest expense
-$2.14M
-$2.13M
-$2.27M
-$2.32M
-$2.21M
-$1.97M
-$1.92M
-$1.76M
Income before taxes
-$1.56M
-$3.46M
-$10.78M
-$7.21M
-$9.4M
-$9.84M
-$12.69M
-$12.68M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$1.56M
-$3.46M
-$10.78M
-$7.21M
-$9.4M
-$9.84M
-$12.69M
-$12.68M
Net income attributable to common shareholders
-$1.69M
-$3.44M
-$10.79M
-$7.16M
-$9.05M
-$10.12M
-$12.68M
-$12.66M
EBITDA
$1.28M
-$772K
-$8.25M
-$4.28M
-$6.44M
-$7.16M
-$10.1M
-$11.03M
Basic earnings per share
-$0.02
-$0.05
-$0.16
-$0.10
-$0.13
-$0.15
-$0.21
-$0.34
Diluted earnings per share
-$0.02
-$0.05
-$0.16
-$0.10
-$0.13
-$0.15
-$0.21
-$0.34
Recent news
Company coverage with links to the original publishers.
Neuronetics priced an underwritten public offering of 18.75 million shares at $1.60 per share, generating approximately $30 million in gross proceeds. The company plans to use proceeds to repay at least $15 million of its term loan with Perceptive Credit Holdings and for general corporate purposes. The offering is expected to close on November 12, 2026, contingent on satisfying customary closing conditions and amendment conditions by November 30, 2026.
Neuronetics (STIM) reported a quarterly loss of $0.02 per share, beating the consensus estimate of $0.08 loss by 75%, with revenues of $41.96 million exceeding expectations by 3.10%. The stock has gained 63.8% year-to-date, outperforming the S&P 500's 10.6% gain. However, the company received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Beta Bionics (BBNX) reported a quarterly loss of $0.52 per share, beating consensus estimates of $0.53 loss, with revenues of $35.51 million exceeding expectations by 0.96%. Despite the positive earnings surprise and a Zacks Rank #2 (Buy) rating, the stock has declined 32.7% year-to-date compared to the S&P 500's 12.1% gain. The company's future performance will depend on management commentary and upcoming earnings estimate revisions.
Integra LifeSciences reported Q3 2026 earnings of $0.59 per share, beating consensus estimates of $0.56, but revenues of $411.18 million missed expectations by 0.81%. The company received a Zacks Rank #3 (Hold) rating, suggesting market-in-line performance ahead. The Medical-Instruments industry ranks in the top 41% of Zacks industries.
Major M&A activity includes Unilever acquiring gummy supplements maker Grüns for $1.2 billion, Bill Ackman's Pershing Square offering $63 billion for Universal Music Group, and Capital One completing its $2.56 billion acquisition of Brex. Meanwhile, several companies face financial distress with Asend Elements and National Road Logistics filing for Chapter 11 bankruptcy, and Saks Global Enterprises restructuring debt from its Neiman Marcus acquisition.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.